Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 18/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007027 | 0.94 | FAAH (0.51) | FAAHNPC1RAB9ADPP4 | |
| SCHEMBL4483992 | 0.85 | FAAH (0.51) | FAAHNPC1RAB9A | |
| SCHEMBL4482673 | 0.85 | FAAH (0.51) | FAAHNPC1RAB9A | |
| SCHEMBL15664837 | 0.83 | FAAH (0.53) | FAAH | |
| SCHEMBL14486889 | 0.83 | FAAH (0.53) | FAAHNPC1RAB9A | |
| SCHEMBL3561081 | 0.83 | FAAH (0.56) | FAAHNPC1RAB9A | |
| SCHEMBL14488223 | 0.82 | HRH4 (0.48) | FAAHNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL14488297 | 0.82 | FAAH (0.52) | FAAH | |
| Hydrochloric Acid SCHEMBL14488352 | 0.82 | FAAH (0.52) | FAAHNPC1RAB9A | |
| SCHEMBL4480897 | 0.81 | FAAH (0.54) | FAAHNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| US-10449192-B2 | Phthalazinone derivatives | KUDO PHARMACEUTICALS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-9566276-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
| CN-105646492-A | Five-membered-aromatic-heterocycte-containing substituted xanthine compound and preparation method and use thereof | 中国医学科学院药物研究所 | 2016-06-08 | — | — | CN | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-7022696-B2 | Piperazino-derivatives and their use as PDE4 inhibitor | ALTANA PHARMA AG (DE) | 2006-04-04 | — | — | US | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006002981-A1 | SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS | Grünenthal GmbH (DE) | 2006-01-12 | — | — | WO | disclosed |
| US-6818644-B1 | FLUORENE-9-CARBOXYLIC AMIDES; INHIBITORS OF MICROSOMAL TRIGLYSERIDE-TRANSFER PROTEIN (MTP); ANTILIPEMIC AGENTS; ATHEROSCLEROSIS, DIABETES, EATING DISORDERS, AND PANCREATITIS | BOEHRINGER INGELHEIM PHARM GMBH & CO, KG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | ATLANTA PHARMA AG (DE) | 2004-07-08 | — | — | US | disclosed |
| EP-1385838-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002085885-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
| EP-1237887-A1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001029028-A1 | 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-26 | — | — | WO | disclosed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | FAAH 3719/4885NPC1 1989/4885RAB9A 3570/4885 |
| US-10449192-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | FAAH 3800/4885NPC1 1933/4885RAB9A 3332/4885 |
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | FAAH 3800/4885NPC1 1933/4885RAB9A 3332/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | FAAH 2648/4885NPC1 1634/4885RAB9A 2788/4885 |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | PDE4A, PDE4B, PDE3A | FAAH 1472/4885NPC1 4254/4885RAB9A 349/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | FAAH 3719/4885NPC1 1989/4885RAB9A 3570/4885 |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | FAAH 3800/4885NPC1 1933/4885RAB9A 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.